Lim, Elgene http://orcid.org/0000-0001-8065-8838
Boyle, Frances
Okera, Meena
Loi, Sherene
Goksu, Sema Sezgin
van Hal, Gertjan
Chapman, Sonya C.
Gable, Jonathon Colby
Chen, Yanyun
Price, Gregory L.
Hossain, Anwar M.
Gainford, M. Corona
Ezquerra, Meritxell Bellet
Funding for this research was provided by:
Eli Lilly and Company
University of New South Wales
Article History
Received: 11 March 2022
Accepted: 12 July 2022
First Online: 1 August 2022
Declarations
:
: EL reports a consulting or advisory (paid to his institution) role with Eli Lilly and Company, Novartis Australia, Pfizer and Roche; institutional research funding from Novartis Australia; travel or accommodation expenses from Eli Lilly and Company; and a patent/royalty/intellectual property for the sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. FB reports a consulting or advisory role with Pfizer, Eli Lilly and Company, Novartis Australia, Roche and Eisai; and travel or accommodation expenses from Novartis Australia. MO has no competing interests to declare. SL reports receiving research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics Astra Zeneca, Roche-Genentech and Seattle Genetics; a consulting or advisory role (not compensated) with Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca and Roche-Genentech; a consulting or advisory role (paid to her institution) with Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Seattle Genetics and Bristol Meyers Squibb; is a Scientific Advisory Board Member of Akamara Therapeutics; and is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York. SSG reports a consulting or advisory role with Novartis, MSD, Roche and Amgen; speakers' bureau company with Eli Lilly and Company, Novartis, Roche, Phizer and BMS; travel, accommodation or congress fees from Pfizer, Novartis, Roche, Astra-Zeneca; and is a primary/sub investigator of many clinical studies sponsored by Roche, MSD, BMS and Novartis. SCC, JCG, YC, GLP, AMH and MCG are full-time employees of Eli Lilly and Company and are Eli Lilly and Company shareholders. MB-E reports personal fees from Pfizer, Novartis, and Eli Lilly and Company; and travel expenses from Pfizer and Roche.